title: Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy).
authors.affiliation: Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
authors.forename: Duane S
authors.initials: DS
authors.lastname: Pinto
authors.forename: David P
authors.initials: DP
authors.lastname: Lorenz
authors.forename: Sabina A
authors.initials: SA
authors.lastname: Murphy
authors.forename: Susan J
authors.initials: SJ
authors.lastname: Marble
authors.forename: Peter M
authors.initials: PM
authors.lastname: DiBattiste
authors.forename: Laura A
authors.initials: LA
authors.lastname: Demopoulos
authors.forename: Christopher P
authors.initials: CP
authors.lastname: Cannon
authors.forename: C Michael
authors.initials: CM
authors.lastname: Gibson
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D001780:Blood Coagulation Tests / Q000592:standards*; D003327:Coronary Disease / Q000628:therapy; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006470:Hemorrhage / Q000139:chemically induced*; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077466:Tirofiban; D014443:Tyrosine / Q000008:administration & dosage* / Q000031:analogs & derivatives
chemical_list: D005343:Fibrinolytic Agents; D014443:Tyrosine; D006493:Heparin; D000077466:Tirofiban